罗格列酮对老年糖耐量减低干预治疗的临床探讨

目的：观察罗格列酮干预老年糖耐量减低的疗效及安全性。方法：选择老年糖耐量减低患者54例，给予罗格列酮4～8mg，1次／d1：3服，连服24周。治疗前、后监测空腹及餐后2h血糖、空腹胰岛素、糖化血红蛋白、血脂、肝功及肾功。结果：治疗前空腹、餐后2h血糖、空腹胰岛素、血脂分别为（6．11±0．09）mmol／1、（8．23±0．19）mmol／1、17～53（26）mU／1、（3．2±0．2）mmol／1，治疗后分别为（5．00±0．27）mmol／1、（8．01±1．13）mmol／1、11～39（15）mU／1、（1．8±0．1）mmol／1，治疗前后差异有统计学意义（P〈0．01～0．05）。结论：罗格列酮治疗老年糖耐量减低安全有效。

Clinical discussion of intervening treatment of Rosiglitazon in low glucose tolerance senile patients

Objective To observe the clinical effects and safety of intervening treatment of Rosiglitazone in low glucose tolerance senile patients.Method Fifty-four senile patients with low glucose tolerance were selected,and medicated orally with Rosiglitazone 4-8 mg,one time a day for continuous 24 weeks.Fasting plasma glucose(FPG),postprandial glucose following meal 2 hours later(PG2H),fasting insulin(FINS),glycosylated hemoglobin(GHbA),plasma lipid,and the functions of liver and renal were detected before and after medication separately.Results FPG,PG2H,FINS,plasma lipid were(6.11±0.09)mmol/L,(8.23±0.19)mmol/L,17-53(26)mU/L,(3.2±0.2)mmol/L before medication respectively;and(5.00±0.27)mmol/L,(8.01±1.13)mmol/L,11-39(15)mU/L,(1.8±0.1)mmol/L after medication,respectively.There was significant difference between before and after medications(P<0.01-0.05).Conclusion It is a very safe and effective therapy of Rosiglitazone in treating low glucose tolerance senile patients.